SanBio Company (4592) Q3 2026 earnings summary

Executive summary

• Achieved conditional and time-limited approval for AKUUGO® in Japan, with plans to launch after NHI price listing and expand into the US market with Phase 3 clinical trials for traumatic brain injury and discussions for ischemic stroke trials in Japan.

• Focused on research and development of cell therapeutic agent SB623 for central nervous system diseases, with significant progress in regulatory approvals and commercialization steps.

Financial highlights

• Operating loss for the nine months ended October 31, 2025 was ¥2,673 million, compared to ¥2,482 million in the same period last year.

• Ordinary loss increased to ¥3,159 million from ¥1,999 million year-over-year.

• Net loss attributable to owners of parent was ¥2,713 million, up from ¥2,152 million year-over-year.

• Research and development expenses totaled ¥1,920 million, mainly related to AKUUGO® approval processes.

• Foreign exchange losses of ¥395 million impacted non-operating expenses.

Outlook and guidance

• Full-year forecast remains unchanged, projecting an operating loss of ¥3,920 million and net loss of ¥4,045 million (net loss per share: ¥56.17).

• No dividend is planned for the fiscal year ending January 31, 2026.